Jack Fertility: Scrapping the Stigma of Men’s Fertility Health

Why It Matters

Male infertility remains under‑diagnosed despite representing a third of infertility cases; Jack Fertility’s accessible, science‑backed test could reshape public health dialogue and empower men to manage their reproductive health proactively.

Key Takeaways

• Home kit uses algorithm to estimate sperm motility after transport
• Privacy, simplicity, and accuracy identified as key drivers for male testing
• Funding hurdles stemmed from investors’ unfamiliarity with male fertility products
• Expansion plans include vasectomy testing, sperm‑freezing, and European rollout

Pulse Analysis

The male side of infertility is often hidden behind cultural taboos, even though clinical data shows that men contribute to roughly one‑third of all infertility cases. Traditional clinics are scarce, wait‑times long, and many men feel uncomfortable seeking help in a female‑focused environment. This gap creates a sizable, untapped market for consumer‑grade diagnostics that respect privacy while delivering clinically relevant insights. Jack Fertility’s approach directly addresses that void, positioning the company at the intersection of health tech, reproductive science, and behavioral change.

Jack Fertility’s kit combines a simple collection tube, a preservative fluid, and a proprietary laboratory ageing algorithm that reconstructs sperm motility as if the sample were analyzed immediately. By partnering with an in‑house research facility, the startup ensures results meet clinical standards without requiring a clinic visit. Users register the kit online, ship it via tracked Royal Mail, and receive a detailed report that benchmarks fertility and tracks changes over the 70‑day sperm regeneration cycle. The technology not only preserves sample integrity but also translates raw data into actionable lifestyle recommendations, turning a once‑intimidating test into a routine health check.

From a business perspective, Jack Fertility illustrates the challenges of financing health‑focused consumer products. Despite securing an Innovate UK grant and FemTech Lab mentorship, the founders faced repeated rejections from investors unfamiliar with male reproductive health needs. Yet the market potential is compelling: aging populations across Europe are driving demand for fertility solutions, and the company’s roadmap includes vasectomy testing, sperm‑freezing services, and a pan‑European rollout. By normalising male fertility testing, Jack Fertility could influence public health policy, encouraging broader integration of men’s reproductive health into national strategies and opening new revenue streams for the burgeoning digital health ecosystem.